News

Wednesday - February 27, 2019

Bayer increases sales and earnings – leader in agriculture after acquisition
Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits/ Net income at 1.695 billion euros, impacted by one-time effects / Core earnings per share at 5.94 euros, above expectations / Net financial debt at 35.679 billion euros, significantly better than expected / Bayer confirms 2019 Group outlook and 2022 targets more

Thursday - June 07, 2018

Bayer closes Monsanto acquisition
Bayer successfully completed the acquisition of Monsanto on Thursday. Shares in the U.S. company will no longer be traded on the New York Stock Exchange, with Bayer now the sole owner of Monsanto Company. Monsanto shareholders are being paid 128 U.S. dollars per share. J.P. Morgan assisted Bayer with processing the purchase price payment for the largest acquisition in the company’s history. According to the conditional approval from the United States Department of Justice, the integration of Monsanto into Bayer can take place as soon as the divestments to BASF have been completed. This integration process is expected to commence in approximately two months. more

News overview

Select Division
Select Country